US Patent Issued to Memorial Sloan Kettering Cancer Center on May 19 for "Bispecific HER2 and CD3 binding molecules" (New York Inventors)

ALEXANDRIA, Va., May 19 -- United States Patent no. 12,630,632, issued on May 19, was assigned to Memorial Sloan Kettering Cancer Center (New York).

"Bispecific HER2 and CD3 binding molecules" was invented by Nai-Kong V. Cheung (New York), Andres Lopez-Albaitero (New York) and Hong Xu (New York).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are compositions, methods, and uses involving bispecific binding molecules that specifically bind to HER2, a receptor tyrosine kinase, and to CD3, a T cell receptor, and mediate T cell cytotoxicity for managing and treating disorders, such as cancer. Also provided herein are uses and methods for managing and treating HER2-related cancers."

The patent was ...